Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 14/20 | 0.60 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.42 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708137 | 0.89 | LPAR1 (0.65) | LPAR1LPAR5LPAR3LPAR2FKBP1A | |
| SCHEMBL968828 | 0.84 | LPAR1 (0.58) | LPAR1LPAR5LPAR3LPAR2FKBP1A | |
| SCHEMBL708862 | 0.84 | LPAR1 (0.71) | LPAR1LPAR5LPAR3LPAR2 | |
| SCHEMBL709264 | 0.84 | LPAR1 (0.61) | LPAR1LPAR5LPAR3LPAR2TUBB1 | |
| SCHEMBL708375 | 0.80 | LPAR1 (0.84) | LPAR1LPAR2FKBP1ATUBB1LMNA | |
| SCHEMBL704803 | 0.80 | LPAR1 (0.62) | LPAR1LMNAHTTSMN1; SMN2TDP1 | |
| SCHEMBL707677 | 0.80 | LPAR1 (0.68) | LPAR1LPAR5LPAR3LPAR2 | |
| SCHEMBL709015 | 0.79 | LPAR1 (0.53) | LPAR1LPAR3TUBB1FFAR1LMNA | |
| SCHEMBL709334 | 0.75 | LPAR1 (1.00) | LPAR1LPAR2 | |
| SCHEMBL709759 | 0.74 | LPAR1 (0.53) | LPAR1TUBB1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875745-B2 | {1-[(2S,3S)-2-(2,3-dihydro-1H-inden-2-ylmethyl)-3-(3,5-dimethoxy-4- methylphenyl)-3-hydroxylpropyl]-1H-pyrrol-3-yl}acetic acid; for urinary system disease selected from the group of prostatic hypertrophy, neurogenic bladder dysfunction disease, dysuria, pollakiuria, night urination and urodynia | ONO PHARMACEUTICAL CO., LTD. (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149595-A1 | Compounds having lysophosphatidic acid receptor antagonism and uses thereof | LPAR2, LPAR1, LPAR5 | LPAR1 2/4885LPAR5 3/4885LPAR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.